Enanta Pharmaceuticals(NASDAQ) ENTA

Enanta creates pills for viral infections and liver diseases. Its medicines help patients fight respiratory and skin conditions. The company builds drugs that stop viruses from growing.

Medicine for Viruses and Lungs

• Hepatitis C Royalties: Royalty payments from AbbVie for glecaprevir, an ingredient that helps treat liver infections.
• RSV Programs: Experimental oral drugs designed to stop respiratory syncytial virus, a common lung infection.
• Immunology Research: Early-stage treatments targeting immune responses that cause hives and chronic skin inflammation.
• COVID-19 Research: Clinical studies focused on blocking the virus that causes COVID-19 using protease inhibitors.

Partnerships and Patent Battles

• Entered a royalty sale agreement with OMERS in April 2023 to receive $200 million.
• Raised $74.75 million in gross proceeds through a public stock offering in October 2025.
• Initiated legal actions against Pfizer in the United States and Europe regarding COVID-19 drug patents.
• Advanced two separate respiratory syncytial virus drug candidates through phase 2 clinical trials.

Focusing on Internal Discovery

Enanta uses a chemistry-based approach to discover all its drug candidates within its own laboratories. This strategy allows the company to maintain full control and ownership over its primary research programs.

A Look at the Numbers

• Revenue was $18.6 million in Q1 2026, up 9.8% from the previous year.
• Net loss reached $11.9 million in Q1 2026, an improvement of 46.4% year over year.
• Operating cash flow was an $11.7 million loss in Q1 2026, an improvement of 30.4%.
• Total cash and marketable securities were $241.9 million as of Dec. 31, 2025.

Bottom Line

Enanta has moved from a reliance on hepatitis royalties to building an internal pipeline of respiratory and skin treatments. The company uses strategic fundraising and patent enforcement to support its long-term clinical research.